Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study

Hee-Seo SON; Cheol-Young OH; Myung-Soo CHOO; Hyeong-Gon KIM; Joon-Chul KIM; Kyu-Sung LEE; Dong-Gil SHIN; Sung-Yong CHO; Seong-Jin JEONG; Ju-Tae SEO; Hana YOON; Hong-Sang MOON; Jang-Hwan KIM.
International Neurourology Journal ; : 119-128, 2022.
Artículo en Inglés | WPRIM | ID: wpr-937706

Documentos relacionados

  1. Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study.
  2. [Cure effect and persistence of treatment with Mirabegron in patients with symptoms of overactive bladder: a multicentre clinical study].